Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study
- PMID: 31918994
- DOI: 10.1016/j.ygyno.2019.12.026
Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study
Abstract
Objective: To assess the feasibility of a novel hysteroscopic catheter to collect fallopian tube cytologic samples and to correlate cytologic findings with histopathology.
Methods: This was a prospective, multicenter, single-arm pilot study. Women undergoing salpingo-oophorectomy for a pelvic mass suspicious for malignancy or for prevention of cancer for BRCA mutation carriers were recruited from 3 gynecologic oncology centers (October 2016-August 2017). Cytologic samples were collected from the fallopian tube using a novel FDA-cleared hysteroscopic catheter and evaluated by a pathologist blinded to surgical or pathologic findings. The correlation between cytologic results and final surgical pathology was assessed.
Results: Of the 50 patients enrolled, 42 were eligible. Hysteroscopies were completed in 40 patients with 78 fallopian tubes, of which 65 ostia (83%) were identified. Of these, 61 (72%) were successfully catheterized resulting in 44 (68%) cytology samples adequate for further evaluation: 5 were classified as positive (3 neoplastic and 2 malignant) and 39 as negative (34 benign and 5 reactive/atypical). A comparison of cytology results with fallopian tube histopathology showed a concordance rate of 95% (42/44). Of the two samples with discordant results, both had positive cytology but negative tubal pathology, and both were stage I ovarian cancers with malignant ovary histology.
Conclusions: Deployment of the device yielded an evaluable cytologic sample in 68% of cases with a high rate of concordance with histopathology. Further evaluation of the device's ability to detect malignancy in high risk populations is warranted.
Keywords: Cytology; Hysteroscopic catheter; Ovarian cancer; Surveillance.
Copyright © 2019 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Sharmila Pramanik reports personal fees from nVision Medical (a Boston Scientific company) during the conduct of this study. The other authors report no conflicts of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical